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Identifying microRNA determinants 
of human myelopoiesis
Megha Rajasekhar1,2, Ulf Schmitz1,2, Stephane Flamant1,2, Justin J.-L. Wong1,2,3,  
Charles G. Bailey1,2, William Ritchie1,2, Jeff Holst  2,4 & John E. J. Rasko1,2,5
Myelopoiesis involves differentiation of hematopoietic stem cells to cellular populations that are 
restricted in their self-renewal capacity, beginning with the common myeloid progenitor (CMP) and 
leading to mature cells including monocytes and granulocytes. This complex process is regulated 
by various extracellular and intracellular signals including microRNAs (miRNAs). We characterised 
the miRNA profile of human CD34+CD38+ myeloid progenitor cells, and mature monocytes and 
granulocytes isolated from cord blood using TaqMan Low Density Arrays. We identified 19 miRNAs 
that increased in both cell types relative to the CMP and 27 that decreased. miR-125b and miR-10a 
were decreased by 10-fold and 100-fold respectively in the mature cells. Using in vitro granulopoietic 
differentiation of human CD34+ cells we show that decreases in both miR-125b and miR-10a correlate 
with a loss of CD34 expression and gain of CD11b and CD15 expression. Candidate target mRNAs 
were identified by co-incident predictions between the miRanda algorithm and genes with increased 
expression during differentiation. Using luciferase assays we confirmed MCL1 and FUT4 as targets of 
miR-125b and the transcription factor KLF4 as a target of miR-10a. Together, our data identify miRNAs 
with differential expression during myeloid development and reveal some relevant miRNA-target pairs 
that may contribute to physiological differentiation.
Myelopoiesis results in the generation of mature myeloid cells: the monocytes, granulocytes, dendritic cells, meg-
akaryocytes and erythrocytes. Differentiation follows a highly regulated series of phases from a hematopoietic 
stem cell (HSC) into increasingly self-renewal- and lineage-restricted progenitor cells. Myelopoiesis begins from 
the common myeloid progenitor (CMP) that gives rise to the mature myeloid cells, but not to the T, B and NK 
cells of the lymphoid lineage.
The classical, mouse-based model of HSC differentiation, devised by the work of Akashi, Kondo and 
Weissman1,2 is relevant to human physiology as confirmed using cells from the bone marrow and umbilical cord 
blood and a specific set of CD markers3–5. In this model, long-term repopulating HSCs give rise to short-term 
HSCs, which in turn lead to multipotent progenitors and then the common lymphoid and myeloid progenitors. 
Human cells with the phenotype CD34+CD38+ have no self-renewing or lymphoid potential and are believed to 
constitute the CMP as well as the further differentiated granulocyte/monocyte progenitor (GMP), the megakar-
yocyte/erythroid progenitor (MEP) and a potential monocyte/dendritic cell progenitor (MDP). These subsets 
can be further differentiated based on expression of CD45RA and CD1354. Together these represent ~1% of 
the mononuclear cell population of the bone marrow4,6. While this hierarchy is generally widely accepted for 
human myelopoiesis7,8, further studies have refined the model by demonstrating a potential for macrophage and 
dendritic cell development from a lymphoid progenitor9 and by defining in exquisite detail several sub-types of 
dendritic cells and monocytes10.
Several extrinsic and intrinsic factors work in concert to determine the fate of stem and progenitor cells as they 
differentiate into mature cells. The primary extrinsic determinants of myeloid differentiation are the cytokines 
granulocyte/macrophage colony stimulating factor (GM-CSF), granulocyte colony stimulating factor (GCSF), 
macrophage colony stimulating factor (MCSF), erythropoietin (EPO), and thrombopoietin (TPO)11. The most 
influential intrinsic factors are believed to be a group of transcription factors, beginning with SCL/TAL-1 and 
RUNX1 in the embryo, followed by PU.1, C/EBPα, IRF8 and GFI112. In addition to these, cell fate decisions 
1Gene & Stem Cell Therapy Program, Centenary Institute, University of Sydney, Camperdown, 2050, Australia. 
2Sydney Medical School, University of Sydney, Sydney, NSW 2006, Australia. 3Gene Regulation in Cancer 
Laboratory, Centenary Institute, University of Sydney, Camperdown, 2050, Australia. 4Origins of Cancer Program, 
Centenary Institute, University of Sydney, Camperdown, 2050, Australia. 5Cell and Molecular Therapies, Royal Prince 
Alfred Hospital, Camperdown, 2050, Australia. Jeff Holst and John E. J. Rasko contributed equally to this work. 
Correspondence and requests for materials should be addressed to J.E.J.R. (email: j.rasko@centenary.org.au)
Received: 23 October 2017
Accepted: 23 March 2018
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2SCienTifiC RepoRtS |  (2018) 8:7264  | DOI:10.1038/s41598-018-24203-7
may also be determined by other means including by post-transcriptional regulators exemplified by microRNAs 
(miRNAs).
MiRNAs are small, non-coding RNA molecules (19–22 nucleotides) that are genomically encoded and are 
involved in most aspects of cellular development and maintenance13. Initially transcribed as a long primary RNA, 
the transcript undergoes sequential cleavage by RNAse III family enzymes Drosha and Dicer to produce the 
mature miRNA which is incorporated into a protein complex named the RNA-induced silencing complex (RISC). 
The miRNA then guides the RISC to the 3′ untranslated regions (3′ UTRs) of messenger RNA (mRNA) molecules 
to which it binds while the RISC inhibits translation of the mRNA (reviewed in ref.14). Due to imperfect sequence 
complementarity each miRNA is predicted to bind hundreds to thousands of target mRNAs however, the degree 
of translational repression observed for each binding site is usually small15. Thus miRNAs are believed to impact 
specific phenotypes by broadly suppressing multiple targets within specific pathways rather than by large effects 
on a small number of targets16.
Determining the role of miRNAs in myelopoiesis has been approached from different angles previously, with 
the focus generally being on unilineage development or activation17–19 or on the transition from HSCs to com-
mitted progenitors20–22. Several of the reported studies have used cell lines such as NB4 or THP-1 differentiated in 
vitro using agents such as retinoic acid, which, it could be argued, may be a better model of myeloid malignancies 
rather than primary myelopoiesis23–25. Nonetheless, these studies have revealed interactions between key mole-
cules in myelopoiesis and miRNAs. Myeloid transcription factors regulate expression of miRNAs and often form 
feedback loops e.g. C/EBP-α and miRs-34a, -223 and -30c26–28; Gfi1 and miRs-21 and -196b29; and several miR-
NAs regulated by PU.130. Conversely, differential expression of several miRNAs such as miR-223 and miR-17–5p, 
and consequent regulation of their targets, is required for normal myelopoiesis18,31.
While the transition of HSCs to progenitors has been previously examined, few studies have directly evaluated 
the influence of miRNAs on cell fate decisions subsequent to the progenitor, particularly in the human context. 
More generally, studies have explored miRNAs in bulk human CD34+ cells, which would encompass both stem 
and progenitor cells, versus mature cells from the same source to identify lineage specific miRs32,33. One previous 
study by Lu et al. (2008) examined human bone marrow derived MEPs to identify miRNAs that influence cell fate 
choice between megakaryocytes or erythrocytes with the identification of miR-150 as crucial in this process34.
To date a comparable investigation during monocytopoiesis or granulopoiesis has not been reported. In this 
study we examined the miRNA profiles of primary myeloid progenitors, monocytes and granulocytes derived 
from human cord blood. We also examined the mRNA and miRNA profiles of the same cells in combination 
with target prediction software. Here we identified and validated targets of two miRNAs with relevance to human 
myelopoiesis.
Results
Isolation of myeloid populations. Myeloid progenitors and monocytes were isolated from human umbil-
ical cord blood by fluorescence activated cell sorting (FACS), following the enrichment of mononuclear cells by 
density gradient centrifugation. We adopted the definition of myeloid progenitors as lin−CD34+CD38+ cells to 
incorporate the populations identified as the CMP, GMP and MEP. This conforms with classifications defined 
by Manz et al. (2002), based on colony forming potential and mRNA expression of relevant genes4. The myeloid 
progenitors in this study were purified using the same strategy, excluding mature cells with a lineage cocktail 
incorporating antibodies against the markers CD3, CD7, CD10, CD11b, CD14, CD19 and CD56, then sorting 
the CD34 and CD38 double positive cells (Fig. 1a). This lin−CD34+CD38+ population represents approximately 
1% of the mononuclear cell fraction of cord blood. We further assessed their myeloid progenitor status using 
colony forming unit (CFU) assays in semi-solid Methocult medium supplemented with cytokines. Our results 
confirmed that the progenitor population isolated by us could give rise to CFU-granulocyte/erythrocyte/mono-
cyte/macrophage (CFU-GEMM), CFU-granulocyte/macrophage (CFU-GM), CFU-granulocyte (CFU-G), CFU-
macrophage (CFU-M), CFU-erythrocyte (CFU-E) and blast forming unit-erythrocyte (BFU-E) (Fig. 1d–f).
Expression of the integrin alpha M molecule (ITGAM), also known as CD11b, was used to identify monocytes 
and granulocytes in the enriched samples. Monocytes were identified as mononuclear cells with dual expression 
of CD11b and the bacterial lipopolysaccharide co-receptor CD14 (Fig. 1b). Granulocyte isolation was performed 
on the cells that separated from the mononuclear cells and settled with the red blood cells using a dextran gra-
dient. During sorting granulocytes were identified following exclusion of contaminating red blood cells using 
CD235a and then isolating the cells positive for both CD11b and the granulocyte-specific carbohydrate adhesion 
molecule CD15 (Fig. 1c). The sorted cells were immediately stored for RNA extraction.
MicroRNA profiling of myeloid cells. Next, TaqMan Low Density Arrays (TLDAs) were used to profile 
the expression of 365 miRNAs, of which 113 were amplified in at least one of the three cell types. In a pairwise 
comparison of gene expression in progenitors vs. monocytes 33 miRNAs were increased in monocytes, while 29 
miRNAs were reduced (≥2-fold) (Fig. 2a and Table 1). When comparing progenitors with granulocytes, 30 miR-
NAs were increased in granulocytes and 36 miRNAs were reduced (≥2-fold) (Fig. 2b and Table 1).
In order to identify miRNAs that are increased with differentiation in general, we combined expression data 
from monocytes and granulocytes. A subset of 19 miRNAs were increased in both monocytes and granulocytes 
compared to progenitors (Fig. 2c and Table 1). miR-223 showed the greatest increase, with levels in granulocytes 
and monocytes 24- and 9-fold higher than in progenitors (Fig. 2d, top panel). Among the commonly increased 
candidates were also several miRNAs that are clustered together in the genome and are often expressed in a sim-
ilar pattern as each other (Fig. 2d, middle and lower panels). Interestingly, a similar comparison of commonly 
down-regulated genes revealed 27 miRNAs that were decreased in both monocytes and granulocytes relative to 
progenitors (Fig. 2e). These include five of the eight members of the miR-10 gene family (miRs-10a, -99a, -100, 
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-125a and -125b, as classified by miRBase) (Fig. 2f, top panel) and also several clustered miRNAs (miRs-20a, -20b 
and -92, Fig. 2f middle and lower panels).
Five differentially expressed miRNAs were chosen for qRT-PCR validation, with expression normalised to 
a snoRNA RNU24 (Fig. 3a). miR-223, miR-125b, miR-10a, miR-196b and miR-135a showed similar patterns 
of expression to that observed in the TLDA data. When measured by qRT-PCR the mean level of miR-223 was 
ten-fold higher in monocytes relative to progenitors, and was sixty-fold higher in granulocytes. miR-125b was 
expressed at ten-fold lower levels in monocytes and granulocytes relative to progenitors, consistent with the 
TLDA results. The Hox-cluster encoded miR-10a could be amplified from all the progenitor samples but only 
from seven monocyte samples and eight granulocyte samples. Mean expression of miR-10a was a hundred-fold 
lower in both monocytes and granulocytes, making the levels too low to be detected from the remaining five 
monocyte and granulocyte samples.
The second Hox-cluster encoded miRNA, miR-196b, was expressed at thirty-fold lower levels in monocytes 
and fifteen-fold lower levels in granulocytes, relative to progenitors. miR-135a could be detected in all the progen-
itor samples, though the levels of miRNA were quite low. It could only be amplified from four monocyte samples 
and two granulocyte samples and showed approximately thirty-fold lower levels in the mature cells relative to the 
progenitor cells.
Two other studies have reported the miRNA expression profiles of differentiating hematopoietic stem and 
progenitor cells. Bissels et al. (2011) compared bone marrow CD133+ (more primitive) with CD133−CD34+ 
cells (less primitive)35 while Liao et al. (2008) studied more differentiated cells and compared CD34+CD38− cells 
with CD34+ cells36. Similarly, Cattaneo et al. (2015) compared miRNA profiles of CD34+CD38− cells (HSCs) 
and CD34+CD38+ cells (hematopoietic progenitor cells; HPCs)20. The miRNA profiles of the progenitors in 
our study are comparable as they could be placed at the next step with their more differentiated phenotype of 
CD34+CD38+. The miRNA profiles in these three studies and in this study were obtained using four different 
profiling platforms and therefore vary in the miRNAs included. Nonetheless, in order to identify miRNAs that 
are increased or decreased with differentiation we compared those that were reported as increasing or decreasing 
with differentiation in these three studies with those in ours.
We found ten miRNAs that decrease with differentiation in at least three of these four studies, suggesting that 
they may be involved in maintenance of a more undifferentiated phenotype and seven miRNAs that increase 
(Table 2). Interestingly, four of the reduced miRNAs, miR-99a, miR-100, miR-125b, miR-125a-5p, are members 
of homologous tricistronic clusters involved in stem and progenitor cell homeostasis37. Therefore there are 12 
miRNAs that increase and 18 that decrease with differentiation from this study that were not reported by the pre-
vious studies of stem cells/progenitors. The miRNAs that increase with differentiation in our study may indicate 
some that are required for a terminally differentiated phenotype (e.g. miR-223 for granulocytes and miR-15b 
Figure 1. Purification of myeloid populations. (a) FACS gating strategy for purifying the CD34+CD38+ 
myeloid progenitor populations. Firstly, mononuclear cells were gated on, then single cells, followed by lineage-
negative cells. (b) Monocytes were identified as the CD11b+CD14+ cells within cord blood mononuclear cells. 
(c) Polymorphonuclear cells were isolated by dextran separation from red blood cells. Granulocytes were then 
sorted and were identified as the CD11bhighCD15high cells, following exclusion of CD235a+ red blood cells. (d–f) 
Myeloid progenitors were plated in semi-solid Methocult medium with the cytokines SCF, IL-3, GM-CSF and 
EPO. Colony types formed include colony forming unit-granulocyte/erythrocyte/monocyte/macrophage (d, 
left), granulocyte/macrophage (d, right), granulocyte (e, left), macrophage (e, right), erythrocyte (f, left) and 
blast forming unit-erythrocyte (f, right). Note: Images d–f are on different scales to emphasize morphological 
features.
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for megakaryocytes) and the ones that decrease tend to be those that help to maintain the stem/progenitor cell 
phenotype (e.g. let-7c).
These data together suggest a signature of miRNA expression associated with differentiation status and matu-
ration within the myeloid lineage. They also provide some evidence of monocyte and granulocyte lineage specific 
miRNAs with varying expression in each of the mature populations.
Decreased expression of miR-10 family members is associated with increased lineage com-
mitment. The miRBase database lists miR-s-10a, -10b, -125a, -125b, -99a, -99b and -100 as members of the 
miR-10 family. As there was a clear association of decreased expression of these miRNAs with more mature phe-
notypes, we further explored two family members, miR-125b and miR-10a in this context.
In initial screening experiments we sought to explore the change in levels of these miRNAs in response to 
short-term liquid culture. FACS purified cord blood CD34+ cells were cultured in medium with serum and 
SCF or IL-3 (Supplementary Figure 1). Cells were sampled at days 1, 2 and 3 and levels of miR-125b and miR-
10a assessed by qRT-PCR. In response to SCF, levels of miR-125b decreased by an average of 40% by day 3. In 
response to IL-3, miR-125b levels decreased by an average of 60%. Levels of miR-10a mirrored this and decreased 
50% by day 3 with SCF and 80% with IL-3.
While SCF and IL-3 by themselves can stimulate granulocyte/macrophage colony formation, the combina-
tion of SCF with GCSF is a more potent and specific inducer of myeloid commitment in CD34+ cells in liq-
uid and semi-solid cultures38. In order to focus on granulocytic commitment using longer culture duration, 
MACS-purified cord blood CD34+ cells were differentiated in vitro using SCF and GCSF and their cell-surface 
expression of CD34, CD11b, CD14 and CD15 assessed. By day 6, expression of CD34 was decreased from approx-
imately 70% to 15% of cells, with a concomitant increase in surface expression of the mature myeloid markers 
CD11b, CD14 and particularly of CD15 (Fig. 3b). Over a similar time course qRT-PCR showed a seven-fold 
decrease in miR-125b and approximately ten-fold decrease in miR-10a by day 9 (Fig. 3c). miR-223 expression was 
Figure 2. MiRNA profiling of cord blood myeloid progenitors, monocytes and neutrophils. Normalised 
TaqMan Low-Density Array (TLDA) profiles of miRNA expression in (a) monocytes vs. myeloid progenitors 
and (b) granulocytes vs. myeloid progenitors from human cord blood. MiRNAs with ≥ 2-fold increased 
expression in the mature cell types are shown in red and those with ≥ 2-fold decreased expression are shown 
in green. (c) Number of miRNAs increased ≥ 2-fold or more in each comparison. (d) Top panel: miRNAs with 
a ≥ 2-fold increase in both cell types. Middle and lower panel: miRNAs that are increased in both cell types 
and are clustered together in the genome. (e) Number of miRNAs decreased ≥ 2-fold in each comparison. (f) 
Top panel: the five miRNAs of the same family (highly similar seeds) that are decreased in both mature cell 
types relative to the progenitor. Middle and lower panels: miRNAs that decreased in both comparisons and are 
clustered together in the genome.
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used as a positive control and showed an approximately three-fold increase by day 9 (Fig. 3c). These data confirm 
the decrease in expression of miR-10a and miR-125b during early myeloid differentiation.
Identification of predicted targets of miR-125b and miR-10a. Affymetrix microarrays were per-
formed on progenitors, monocytes and granulocytes that had been FACS isolated as described above from three 
cord blood samples. Unsupervised hierarchical clustering showed that the gene expression of the two mature cell 
types was closer to each other than to the progenitors (Supplementary Figure 2). To assess the differences in gene 
expression between the progenitors and each of the mature populations, we examined the top 2000 genes that 
were increased and decreased in monocytes vs. progenitors and in granulocytes vs. progenitors (Fig. 4a and b). 
Gene ontology analysis of these sets showed that the differentially expressed genes were enriched in pathways 
pertaining to the acquisition of features of mature myeloid cells (Table 3). In the comparison of progenitors with 
mature monocytes the most significantly over-represented pathways include ‘regulation of myeloid leukocyte 
mediated immunity’, ‘toll-like receptor signalling pathway’ and ‘pattern recognition receptor signalling pathway’. 
In progenitors versus granulocytes the most significantly over-represented pathways included ‘granulocyte activa-
tion’, ‘rRNA processing’ and ‘nonsense-mediated decay’. These results further confirm the identity and maturation 
status of the cells used in our study.
In order to identify mRNA targets of our miRNAs of interest from among these differentially expressed genes, 
we first considered bioinformatically-predicted targets of the miRNAs using the miRanda algorithm39,40, which 
Increased in monocytes and 
granulocytes vs. progenitors




































Increased in monocytes and decreased in granulocytes
miR-339
miR-151
Table 1. MicroRNAs that are differentially expressed by at least 2-fold between myeloid progenitors and 
corresponding monocytes and granulocytes.
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uses sequence composition, conservation and thermodynamic stability as criteria for predicting miRNA tar-
get sites. This algorithm applies a sensitive method that has a high relative overlap with predictions from other 
algorithms. The top 1000 gene candidates that were increased in monocytes and granulocytes versus myeloid 
progenitors were combined with the target predictions for miR-125b and miR-10a (Fig. 4c and d). The resulting 
162 candidates for miR-125b and 161 candidates for miR-10a that were both predicted targets and had inverse 
expression patterns to the miRNAs were investigated further through literature searches. This process resulted in 
the selection of three putative targets for confirmatory testing using the luciferase reporter assay (MCL1, FUT4 
Figure 3. Decreased expression of miR-125b and miR-10a is associated with increased lineage commitment 
of myeloid progenitors. (a) qRT-PCR validation of miRNAs differentially expressed in TLDA experiments 
(n = 10). The small nucleolar RNA RNU24 was used for normalisation. Whiskers show 5th and 95th percentiles. 
miR-135a could not be amplified from most monocyte and neutrophil samples; the results have therefore been 
shown here as expression relative to RNU24 only. Differences were tested by ANOVA, Kruskal Wallis test with 
Dunn’s post test. ***p < 0.001, **p < 0.01, *p < 0.05, n.s. = not significant. (b) Expression of CD34, CD11b, 
CD14 and CD15 on MACS-purified cord blood CD34+ cells cultured for 6 days with SCF (100 ng/mL) and 
GCSF (10 ng/mL). (c) The same cytokines were used to in vitro differentiate FACS-purified CD34+ cells and 
their levels of miR-223, miR-125b and miR-10a assessed by q-RT-PCR over nine days (n = 3). Graphs show 
mean ± SEM.
Increased in 
Bissels et al. and 
this study
Increased in 
Liao et al. and 
this study
Increased in 









Bissels et al. and 
this study
Decreased in 
Liao et al. and 
this study
Decreased in 
Cattaneo et al. 
and this study
Decreased in 
Bissels et al. and 
Cattaneo et al.






Table 2. Stem/progenitor microRNAs that consistently increase and decrease during differentiation as 
demonstrated by Bissels et al.35, Liao et al.36, Cattaneo et al.20 and this study.
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and KLF4). The increase in MCL1, FUT4 and KLF4 expression during myeloid differentiation as determined in 
the microarray analysis is shown in Supplementary Figure 3.
Experimental confirmation of targets of miR-125b and miR-10a by luciferase assays. FUT4 
mRNA has two predicted miR-125b binding sites (~100 nt apart) in its 3′ UTR, whilst MCL1 mRNA also con-
tains a predicted miR-125b target site in its 3′ UTR (Fig. 5a). PhastCons scores for FUT4 and MCL1 miR-125b 
binding sites indicate that their seed regions are highly conserved in vertebrates (Fig. 5a). KLF4 mRNA contains a 
predicted miR-10a binding site, which is also highly conserved in vertebrate species (Fig. 5a). To experimentally 
validate these miRNA-target interactions we used HeLa cells in which we had confirmed the presence of endog-
enously expressed miR-125b and miR-10a by qRT-PCR (Supplementary Figure 4). HeLa cells were transfected 
with luciferase reporter vectors carrying either WT or mutated (mut) 3′ UTRs of interest located downstream of 
luciferase. If repression of the WT vector relative to the mut vector was observed, they were then co-transfected 
Figure 4. Identifying miRNA targets. Gene expression profiling was performed on progenitors, monocytes 
and granulocytes isolated from three human cord blood samples (1,2,3) using Affymetrix microarrays. The 
heatmaps show levels (log 2) of the top 2000 differentially expressed genes between (a) progenitors and 
monocytes and (b) progenitors and granulocytes. The identity of transcripts exhibiting higher expression in 
the mature cell types relative to progenitors was combined with target predictions for miR-125b (c) and miR-
10a (d), both miRNAs with lower expression in the mature cells. The resulting 162 and 161 genes respectively 
(circled in red in c and d) that had inverse expression with the miRNA as well as being predicted targets were 
analysed further.
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with miR-125b or miR-10a inhibitor (125I/10I) or negative control (NC) inhibitor to knock down the miRNA 
expression and ‘rescue’ the repression.
As the 3′ UTR of FUT4 has two predicted binding sites for miR-125b (Fig. 5a), repression of the WT 3′ UTR 
was tested alongside single mutants of each of the binding sites (Site 1 mut and Site 2 mut), and a construct with 
both seed regions disrupted (double mut). At the lower inhibitor concentration of 10 nM the luciferase signal 
from the WT vector with NC was only 66% of the double mut vector indicating repression by cell intrinsic miR-
125b (Fig. 5b). This recovered to 90% when the WT vector was co-transfected with 10 nM 125I (p < 0.05). Upon 
mutation of miR-125b Site 1 in FUT4, the luciferase signal decreased to 79% of the double mut vector (i.e. 21% 
lower signal due to miR-125b binding the intact Site 2). This Site 1 mut vector was completely de-repressed when 
co-transfected with 125I (p < 0.05). Conversely, the vector containing the mutant Site 2 had a luciferase signal that 
was 90% of the double mut vector, i.e. only a modest 10% signal decrease due to miR-125b-mediated repression 
through the intact Site 1. Upon addition of 125I to the Site 2 mutant construct no de-repression was observed, 
confirming that minimal repression occurred through binding Site 1.
A similar pattern was observed when the same experiment was repeated at the higher concentration of the 
miRNA inhibitors. At 50 nM, the FUT4 WT vector was de-repressed by 39% with 125I vs. double mut (Fig. 5c, 
p < 0.01) and the Site 1 mut vector was de-repressed by 37% with 125I (p < 0.05), as a result of the effect of miR-
125b/125I on the intact, conserved binding Site 2 in this vector. As at the lower inhibitor dose, there was no signif-
icant difference in luciferase expression in the Site 2 mut vector between NC or 125I transfected samples, due to 
minimal repression by miR-125b binding to the intact site 1 in this vector. These data together suggest that FUT4 
expression is modulated by miR-125b by repression of the transcript through two binding sites, with most of the 
repression due to the more conserved of the two sites.
Luciferase vectors carrying either the WT or mut MCL1 3′ UTR were co-transfected with NC or 125I inhib-
itors at 10 nM or 50 nM. At 10 nM NC inhibitor, the luciferase signal of the WT vector was only 83% of the 
GO biological process complete Fold enrichment p-value
Progenitors vs. Monocytes
regulation of mast cell activation (GO:0033003) 3.98 4.22E-02
regulation of myeloid leukocyte mediated immunity (GO:0002886) 3.98 4.22E-02
regulation of B cell proliferation (GO:0030888) 3.48 2.19E-02
regulation of alpha-beta T cell activation (GO:0046634) 3.30 5.91E-03
toll-like receptor signaling pathway (GO:0002224) 3.00 1.84E-02
purine ribonucleoside biosynthetic process (GO:0046129) 2.95 1.56E-02
purine nucleoside biosynthetic process (GO:0042451) 2.95 1.56E-02
nucleoside biosynthetic process (GO:0009163) 2.94 5.12E-04
pattern recognition receptor signaling pathway (GO:0002221) 2.92 2.17E-03
glycosyl compound biosynthetic process (GO:1901659) 2.89 7.45E-04
purine nucleotide biosynthetic process (GO:0006164) 2.89 2.12E-04
positive regulation of lymphocyte proliferation (GO:0050671) 2.88 1.48E-04
positive regulation of mononuclear cell proliferation (GO:0032946) 2.84 2.14E-04
ribonucleoside biosynthetic process (GO:0042455) 2.82 6.51E-03
positive regulation of leukocyte proliferation (GO:0070665) 2.81 1.79E-04
Progenitors vs. Granulocytes
maturation of LSU-rRNA (GO:0000470) 6.41 2.42E-04
neutrophil activation (GO:0042119) 5.87 3.73E-02
granulocyte activation (GO:0036230) 5.82 1.51E-02
ribosomal large subunit biogenesis (GO:0042273) 3.88 3.31E-04
SRP-dependent cotranslational protein targeting to membrane (GO:0006614) 3.34 2.03E-04
myeloid leukocyte activation (GO:0002274) 3.32 4.57E-05
viral gene expression (GO:0019080) 3.14 2.57E-05
cotranslational protein targeting to membrane (GO:0006613) 3.08 1.11E-03
protein targeting to ER (GO:0045047) 3.08 1.11E-03
rRNA metabolic process (GO:0016072) 3.03 5.71E-13
rRNA processing (GO:0006364) 3.03 1.45E-12
nuclear-transcribed mRNA catabolic process, nonsense-mediated decay (GO:0000184) 3.03 2.55E-04
mitochondrial translational elongation (GO:0070125) 3.02 2.71E-02
ribosome biogenesis (GO:0042254) 2.99 1.45E-15
translational termination (GO:0006415) 2.99 1.29E-02
Table 3. The top 15 categories from gene ontology analysis performed on the top 2000 differentially expressed 
transcripts using the Panther database’s statistical over representation test with Bonferroni correction (www.
pantherdb.org).
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mut vector (Fig. 5d) indicating repression by miR-125b. When co-transfected with 125I the WT signal recov-
ered to 96% of the mut, though this was not significant. At the higher inhibitor concentration of 50 nM a small 
non-specific inhibition was observed (31% in WT + NC vs. 10 nM and 35% in mut + 125I vs. 10 nM), however 
de-repression as a result of specific inhibition of miR-125b was still observed. At 50 nM, the WT luc signal was 
63% of mut with NC, but recovered to 93% upon addition of 125I (p < 0.01), suggesting that miR-125b does reg-
ulate the expression of MCL1.
The KLF4 gene has one predicted binding site for miR-10a in its 3′ UTR. Luciferase assays comparing the 3′ 
UTR with intact (WT) or mutated (mut) versions of this binding site showed modest but consistent and signif-
icant repression through this binding site (Fig. 5e). Repression could be recovered upon addition of 10I (14% 
de-repression at 10 nM, p < 0.05; 11% de-repression at 50 nM). The dose of the inhibitor did not affect the degree 
of de-repression.
In summary, luciferase reporter assays confirmed both MCL1 and FUT4 as direct targets of miR-125b and 
KLF4 as a target of miR-10a.
Discussion
MicroRNAs are crucial regulators of differentiation and lineage enforcement in the hematopoietic system41. 
While studies have examined miRNA profiles of bulk CD34+ cells, no study has specifically examined myeloid 
progenitors and their progeny concurrently. This study presents a miRNA profile of human myeloid progenitors 
Figure 5. Gene targets of miR-125b and miR-10a. Luciferase reporter assays performed in HeLa cells 
transfected with the WT or mutated 3′ UTR binding site from (a) MCL1, (b,c) FUT4 or (d) KLF4. The 3′ 
UTRs were cloned into a pSiCHECK2 vector and transfected with or without a specific inhibitor of mir-125b/ 
miR-10a or a non-specific control at 10 nM or 50 nM. The one predicted binding site in the MCL1 and KLF4 
3′ UTRs were tested, while the two binding sites in FUT4 were each tested alone (Site 1 mutant and Site 2 
mutant) and together (Double mutant). Each experiment was performed 3 times, each in triplicate. Graphs 
show mean ± SEM. Groups were tested by a two-way ANOVA with Bonferroni post tests. **p ≤ 0.01, * p ≤ 0.05, 
n.s. = not significant.
www.nature.com/scientificreports/
1 0SCienTifiC RepoRtS |  (2018) 8:7264  | DOI:10.1038/s41598-018-24203-7
and corresponding mature monocytes and granulocytes performed on highly pure and clearly defined primary 
cells. We identified miRNAs that are commonly increased and decreased upon differentiation in both lineages 
and also those that are unique to each lineage. For example, we demonstrate the pattern of expression of miR-
125b in primary human cells, whereas previous data were obtained using murine cells. We also identified and 
experimentally validated some novel targets of miR-125b and another myeloid-relevant miRNA, miR-10a in this 
particular cellular context.
The role of miRNAs in myeloid leukaemia has been reported extensively42, however close examination of their 
role in primary human non-leukaemic stem and progenitor cells has been relatively limited. We observed a con-
sistent pattern in the miRNA profile of our progenitor cells, and those previously reported in CD34+ cells21,32. This 
adds validation to the miRNAs generally identified as stem/progenitor-expressed (Table 2). In addition to this our 
data have highlighted human hematopoietic differentiation associated miRNAs (Table 1).
While studies by Bissels et al., Liao et al. and Cattaneo et al. focused on identifying miRNAs in more primitive 
stem cells20,35,36 our data identify miRNA changes after the cells pass these early stages and move towards maturity. 
The importance of the miRNAs we have identified in this manner are highlighted by the roles of some of them 
in other models. For instance, of the miRNAs that decrease with hematopoietic differentiation in our analysis, 
mouse studies have shown that a decrease in miR-146a is crucial for megakaryocytopoiesis43 and a decrease in the 
miR-99a/miR-125a cluster is important for loss of stemness as the cells mature44. Similarly, an increase in miR-
142-3p is necessary for differentiation of myeloid cell lines45 and an increase in miR-16 is necessary for erythro-
poiesis46. Several of the miRNAs identified by us as relevant for monocyte or granulocyte differentiation have also 
been reported in in vitro models of human myeloid differentiation22,33.
The upregulation of miR-223 we observed during monocytopoiesis and granulopoiesis, has also been recently 
shown31, but with their additional observation of miR-223 being maintained at low levels during erythropoiesis. 
The authors further show that the lineage-specific expression levels of miR-223 are fine-tuned by the coordinated 
recruitment and function of different lineage-specific transcription factors to the miR-223 regulatory regions31. 
The functional role of miR-223 in granulopoiesis is realized through a regulatory circuit involving the transcrip-
tion factors C/EBPβ, PU.1, NFI-A and C/EBPα47. miR-223 itself represses the expression of NFI-A and other 
transcription factors that are important in hematopoietic differentiation processes such as MEF2C, a transcrip-
tion factor that promotes myeloid progenitor proliferation48, LMO2, a key regulator of erythropoiesis49, and E2F1, 
the master regulator of cell-cycle progression27. An overview summarising the miR-223 regulatory circuitry in 
myeloid differentiation is illustrated in Fig. 6a.
In addition to these miRNAs that have been previously reported, we have also identified some miRNAs that 
have not been studied in the context of myeloid differentiation, such as miR-127 and miR-484. Both of these 
miRNAs have roles defined predominantly in cancer50–52 and may provide future opportunities for further 
investigation.
The cytokines SCF and IL-3 are often used in combination and with other cytokines for ex vivo expansion 
of hematopoietic stem cells53. Prior to our experiments in primary CD34+ cells, we tested the short-term effects 
of these cytokines on levels of miR-125b and miR-10a and found them to cause a relatively modest decrease in 
their levels. These findings correlate well with previous reports of these cytokines having a similar modest effect 
on granulocyte/macrophage colony formation in semi-solid and liquid cultures38. To delve deeper into lineage 
commitment and the role of our miRNAs of interest, we focused on granulopoiesis and extended the culture for 
longer. Cytokine mediated in vitro differentiation of progenitors towards the granulocytic phenotype with GCSF 
(and SCF) resulted in the decrease of both miR-125b and miR-10a to a much greater degree (approx. 10-fold), and 
correlated well with acquisition of differentiation markers over the same period.
Several studies in the mouse have identified miR-125b and family member miR-125a as important for various 
aspects of primitive and leukaemic hemopoiesis54. In terms of the myeloid lineage, the earliest report by Bousquet 
et al. showed that a common translocation in AML results in miR-125b overexpression55. Overexpression of miR-
125b resulted in various leukaemias in mice56. In fact, several groups have over-expressed miR-125b in the mouse 
hematopoietic system using different methods56–58 and have all observed various myeloproliferative disorders 
depending on the method and degree of overexpression. Together these studies also report that the highest level 
of miR-125b is found in long-term HSCs, with levels progressively decreasing in more differentiated progenitors. 
The important roles of miR-125b and miR-125a in human myelopoiesis is highlighted by their frequent dysregu-
lation in various myeloid malignancies (reviewed in ref.54). However, little has been reported regarding miR-125b 
in lineage definition of primary cells such as granulocytes.
In mouse, levels of miR-125b (and miR-125a) decrease with increasing granulocyte maturity59. In order to 
understand dynamic changes, two studies have examined the role of miR-125b in the murine IL-3 dependent 
promyelocytic cell line 32D60,61. Both studies report that 32D cells have very low levels of miR-125b, but Surdziel 
et al. found that miR-125b levels increased upon GCSF-induced differentiation61. Our experiments, performed 
with primary human cells found the contrary; that miR-125b levels decreased during granulocytic differentiation 
with GCSF, agreeing with findings in primary murine granulocytes59. Our findings are further supported by two 
studies involving miRNA expression at different stages of human neutrophil maturation19,62. Surdziel et al. and 
Bousquet et al. observed that over-expression of miR-125b in murine 32D cells resulted in increased proliferation 
and maintenance of an immature blast cell phenotype60,61. These findings, coupled with our observation that 
miR-125b levels decrease with increasing maturity, suggest that reduced miR-125b is necessary for normal (i.e. 
non-dysplastic) granulocyte development.
We anticipate that miR-125b achieves its regulatory effects through repression of target mRNA molecules. 
MiRNA target prediction algorithms use various parameters including degree of complementarity with target 
mRNA site, miRNA and binding site conservation and number of sites per mRNA to make their predictions 
across all transcripts63. In order to identify transcripts of relevance, we validated transcripts that were both pre-
dicted targets and expressed.
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The first miR-125b target we validated was FUT4. FUT4 encodes a member of the fucosyltransferase family, 
that produce carbohydrate moieties on the surface of cells that act as ligands for selectins and facilitate granu-
locyte adhesion to, and rolling on, endothelial cells. FUT4 is responsible for fucosylating the CD15 cell surface 
antigen in monocytes and promyelocytes64, as well as the production of ligands for P- and L- selectin in conjunc-
tion with another fucosyltransferase, FUT765,66. The levels of FUT4 (and FUT7) transcripts increase in response 
to GCSF, along with E-selectin ligands on immature and late mature granulocytes, as well as levels of E-selectin 
on endothelium67. These reports combined with our findings that FUT4 is a target of miR-125b also highlight an 
important relationship between GCSF, miR-125b and FUT4 in the development and function of myeloid cells. 
Interestingly, FUT7 which encodes a similar enzyme expressed in myeloid cells, also has a predicted binding site 
for miR-125b in its 3′ UTR, though this was not experimentally validated. These observations add further evi-
dence that decreasing expression of miR-125b during myeloid differentiation contributes to the development of 
various lineage-specific and lineage-defining features.
The second validated miR-125b target was MCL-1, which encodes an anti-apoptotic member of the Bcl-2 
family. A regulatory relationship between this miRNA/mRNA pair has been reported in various cancers68–70 
but not in a myeloid context, where MCL-1 plays an important role. Conditional knock-out mice lacking Mcl-1 
in neutrophils and macrophages develop with no neutrophils and severely depleted monocytes71,72. These mice 
have increased numbers of immature myeloid precursors in the bone marrow. The administration of GCSF did 
not lead to increased peripheral blood granulocytes, suggesting that this process requires MCL172. Our find-
ings that miR-125b expression is decreased in response to GCSF and that miR-125b represses the mRNA for 
MCL1 suggests a regulatory relationship between this miRNA/mRNA pair and the process of GCSF-mediated 
granulopoiesis.
In summary, miR-125b targets are central to regulating important organismal processes including apoptosis, 
innate immunity, inflammation and hematopoietic differentiation54. During hematopoietic differentiation, miR-
125b regulates a number of genes including cytokines and transcription factors critical for lymphoid and myeloid 
development (summarised in Fig. 6b). These include transcription factors BLIMP-1 and IRF-4 during human 
B-lineage differentiation54 and IFNG, IL2RB, IL10RA and PRDM1 during T-cell differentiation73. miR-125b also 
represses the expression of the RNA-binding protein Lin-28 which has been shown to be an important regulator 
of hematopoietic development74. In myelopoiesis, miR-125b is both induced by GCSF and negatively regulates 
GCSF expression via a feedback loop54 and also targets transcription factors STAT3, c-JUN and JUND and the 
pro-apoptotic effector BAK161. We have now shown that the miR-125b regulatory circuitry is de-repressed during 
myeloid differentiation leading to an upregulation of FUT4 and MCL1 (Fig. 6b).
The second miRNA examined in this study, miR-10a, also exhibits decreasing expression during differenti-
ation. Previously, a decrease in miR-10a has been reported during megakaryocytopoiesis75 and knock down of 
miR-10a in CD133+ progenitors can induce megakaryocytic differentiation via the transcription factor HOX1A76. 
Figure 6. The miR-223, miR-125b and mir-10a regulatory circuits in human hematopoiesis. miR-223 
regulates myeloid differentiation via the transcription factors LMO, MEF2C, NFI-A, and E2F1. The latter two 
are themselves negative regulators of miR-223 expression and thus fine-tune miR-223 in a negative feedback 
loop (a). miR-125b is involved in the regulation of T-cell and B-cell differentiation as well as granulopoiesis by 
repressing the expression of a number of different transcription factors. We found that miR-125b expression is 
inhibited by IL-3 and SCF, among other regulators (b). miR-10a is another regulator of myeloid and lymphoid 
differentiation targeting BCL-6 and NCOR2 in lymphopoiesis, USF2 and HOXA1 in megakaryocytopoiesis, 
and KLF4 in monocytopoiesis.
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An outstanding potential target of this miRNA was the transcription factor KLF4. While KLF4 is best known as 
one of the four factors necessary for reprogramming somatic cells into induced pluripotent stem cells, KLF4 is 
also a crucial transcription factor for monocyte development from CMPs, acting downstream of PU.177. While 
the targeting of KLF4 by miR-10a has been previously suggested to be relevant in AML78, we have shown that the 
decrease in miR-10a expression upon primary myeloid differentiation and the consequent release of repression 
may be necessary for monocytopoiesis (Fig. 6c).
Other hematopoietic regulators that are targets of miR-10a repression include BCL-6 and NCOR2, transcrip-
tional repressors involved in T cell differentiation79. In lymphopoiesis miR-10a expression is induced by retinoic 
acid and TGFß79. Apart from the validated target HOX1A, qRT-PCR-based target validation suggests the cell 
growth inducer USF2 as another target of miR-10a important in megakaryocytopoiesis80.
In summary, by examining primary human cells at defined points in myeloid differentiation we have identified 
miRNAs that direct specific targets, with potential for great impact in this cellular context. Our data identify a 
miRNA profile of myeloid progenitor cells, extending previous information in the field on more primitive stem 
cells. We further identified changes in the levels of these miRNAs as the cells mature into two separate myeloid 
lineages. We focused on two miRNAs miR-125b and miR-10a and uncovered their potential role in this process 
by identifying their likely mRNA targets. We provide biological validation of some of these targets revealing fur-
ther their specific roles in the development of mature monocytes and granulocytes from the myeloid progenitor.
Materials and Methods
Cord blood collection and cell isolation. All research and procedures were performed in accordance with 
all relevant guidelines and regulations. Human cord blood from healthy donors was obtained from the Sydney 
Cord Blood Bank following informed consent according to approved protocols (X06-0153 and X09-0111) from 
the Sydney Local Health District Human Research Ethics Committee. Typically, samples contained 30–60 mL of 
cord blood with added citrate-dextrose anti-coagulant (ACD-A). Following separation using Ficoll-Paque the 
mononuclear cells were collected for isolation of monocytes and progenitors. The granulocytes were further iso-
lated by centrifugation and red cell lysis following layering over a solution of 3% (w/v) dextran (Sigma-Aldrich; 
Sydney, Australia). In some experiments (indicated in text) CD34+ cells were enriched from the mononuclear 
cell fraction using MACS beads and a positive selection kit (Cat # 130-046-702; Miltenyi Biotec), following the 
manufacturer’s instructions.
Flow cytometry. All antibodies used for FACS staining were obtained from Biolegend (San Diego, 
California, USA). The lineage (lin) cocktail comprised antibodies against CD3 (clone HIT3a), CD7 (MEM-186), 
CD10 (HI10a), CD11b (ICRF44), CD14 (M5E2), CD19 (HIB19) and CD56 (MEM-188). The antibodies against 
CD34, CD38 and CD235a were from the following clones respectively: 4H11, HIT2 and HIR2. Cells were sorted 
to >90% purity on either a BD FACS Vantage or FACS Aria. Analytical flow cytometry was performed on a BD 
FACS Canto.
Methocult assays. FACS purified myeloid progenitor cells were resuspended in Iscove’s Modified Dulbecco’s 
Medium (IMDM) then added to methylcellulose containing the cytokines GM-CSF, EPO, interleukin-3 (IL-3) 
and stem cell factor (SCF) (Methocult, H4434; Stem Cell Technologies) and plated in triplicate into 35 mm Petri 
dishes (1.1 mL/dish). The plates were incubated at 37 °C, 5% CO2 in a humidified environment for 10–16 days. 
Colony formation was observed using a MZFLIII microscope (Leica Microsystems, Wetzlar, Germany) and pho-
tographed with a DFC500 camera attached (Leica).
TaqMan® Low Density Arrays (TLDA) and miRNA assays. Ten cord blood samples were used for 
miRNA profiling. MiRNA profiling was performed using TaqMan Low Density Arrays (TLDAs – early access 
version; Applied Biosystems; Foster City, California, USA). Two TLDAs were performed for each cell type with a 
pool of 5 samples on each array. RNA was extracted from cells using Trizol reagent (Invitrogen; Sydney, Australia) 
following the manufacturer’s instructions. A total of 100 ng of RNA was reverse transcribed using Megaplex 
primers (Human Pool set v1, pre-release evaluation version; Applied Biosystems). The cDNA and master-mix was 
loaded on to the TLDA card and amplified using an Applied Biosystems 7900HT Fast Real-Time PCR System. 
The raw data were first analysed using RQ Manager software (version 1.2; Applied Biosystems) and then using 
Qiagen’s GeneGlobe Data Analysis Centre: (http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php). 
Validation of array results was performed using TaqMan miRNA Assays on the 10 samples used for the array 
individually. All qRT-PCRs performed in this study to amplify specific miRNAs were undertaken using TaqMan 
miRNA assays specific for the miRNA of interest on a Corbett Rotor Gene (RG 3000; Qiagen, Doncaster, Victoria, 
Australia).
Microarrays. Total RNA from myeloid progenitors, monocytes and granulocytes isolated from human cord 
blood was extracted using TRIzol reagent (Life Technologies) and profiled using Affymetrix GeneChip Gene 1.0 
ST human arrays. The raw data were processed using the RMA method from the R Bioconductor ‘oligo’ package 
for background subtraction, normalization, and summarization of probe level data. They were then plotted as 
heat maps using the web-based tool Morpheus (software.broadinstitute.org/morpheus).
Luciferase assays. The sequences of 3′ UTRs used for luciferase reporter assays were PCR-amplified from 
normal human genomic DNA and sequence verified, then cloned into the dual luciferase vector pSiCHECK-2™ 
and sequence verified again. To create mutant miRNA binding site vectors, mutagenesis was performed using 
the enzyme Phusion® (Thermo Fisher). For the assay the plasmids were transfected into HeLa cells using 
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Lipofectamine™2000 (Invitrogen; Carlsbad, CA, USA) according to the manufacturer’s instructions. miRIDIAN 
hairpin inhibitor control siRNA (IN-001005-01-05) or siRNA targeting miR-125b and miR-10a (IH-300595-
05, IH-300549-05 respectively, all from Thermo Scientific Dharmacon) were used to suppress miRNA activ-
ity. Transfected cells were incubated for 24 h at 37 °C, 5% CO2 followed by lysis. A dual luciferase assay using 
Dual-Glo Stop & Glo substrate (Promega) was performed on a Victor2 Wallac Plate Reader.
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